×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XENE – xenon pharmaceuticals inc. - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XENE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/19
09:23 pm
xene
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting [Yahoo! Finance]
Medium
Report
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting [Yahoo! Finance]
4/19
06:00 pm
xene
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
Medium
Report
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
4/15
08:30 am
xene
Xenon to Present at Upcoming Investor Conferences
Low
Report
Xenon to Present at Upcoming Investor Conferences
4/10
06:17 am
xene
Xenon Pharmaceuticals (XENE) had its "sell (d-)" rating reaffirmed by Weiss Ratings.
Low
Report
Xenon Pharmaceuticals (XENE) had its "sell (d-)" rating reaffirmed by Weiss Ratings.
4/7
08:30 am
xene
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
Low
Report
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
3/27
09:00 pm
xene
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know [Yahoo! Finance]
Low
Report
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know [Yahoo! Finance]
3/16
08:43 am
xene
Xenon Pharmaceuticals (XENE) had its price target lowered by Wedbush from $64.00 to $63.00. They now have an "outperform" rating on the stock.
Low
Report
Xenon Pharmaceuticals (XENE) had its price target lowered by Wedbush from $64.00 to $63.00. They now have an "outperform" rating on the stock.
3/15
05:47 am
xene
Xenon Pharmaceuticals (XENE) Climbs 31.7% as Epilepsy Treatment Moves Forward [Yahoo! Finance]
Low
Report
Xenon Pharmaceuticals (XENE) Climbs 31.7% as Epilepsy Treatment Moves Forward [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/26/2026
04:01 pm
XENE
xenon pharmaceuticals inc. - common shares
MISS
Report
-3.8%
xenon pharmaceuticals inc. - common shares
11/3/2025
04:01 pm
XENE
xenon pharmaceuticals inc. - common shares
BEAT
Report
-4.9%
xenon pharmaceuticals inc. - common shares
8/11/2025
04:01 pm
XENE
xenon pharmaceuticals inc. - common shares
BEAT
Report
5.5%
xenon pharmaceuticals inc. - common shares
5/12/2025
04:01 pm
XENE
xenon pharmaceuticals inc. - common shares
BEAT
Report
-17.4%
xenon pharmaceuticals inc. - common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/13
04:01 pm
xene
Form 8-K Xenon Pharmaceuticals For: Apr 07
Low
Report
Form 8-K Xenon Pharmaceuticals For: Apr 07
3/13
08:17 pm
xene
Form 4 Xenon Pharmaceuticals For: Mar 12 Filed by: DiFabio Andrea
Low
Report
Form 4 Xenon Pharmaceuticals For: Mar 12 Filed by: DiFabio Andrea
3/13
08:17 pm
xene
Form 4 Xenon Pharmaceuticals For: Mar 12 Filed by: KENNEY CHRISTOPHER JOHN
Low
Report
Form 4 Xenon Pharmaceuticals For: Mar 12 Filed by: KENNEY CHRISTOPHER JOHN
3/13
08:16 pm
xene
Form 4 Xenon Pharmaceuticals For: Mar 12 Filed by: MORTIMER IAN
Low
Report
Form 4 Xenon Pharmaceuticals For: Mar 12 Filed by: MORTIMER IAN
3/13
07:51 pm
xene
Form 144 Xenon Pharmaceuticals Filed by: KENNEY CHRISTOPHER JOHN
Low
Report
Form 144 Xenon Pharmaceuticals Filed by: KENNEY CHRISTOPHER JOHN
3/13
07:50 pm
xene
Form 144 Xenon Pharmaceuticals Filed by: MORTIMER IAN
Low
Report
Form 144 Xenon Pharmaceuticals Filed by: MORTIMER IAN
3/13
07:50 pm
xene
Form 144 Xenon Pharmaceuticals Filed by: DiFabio Andrea
Low
Report
Form 144 Xenon Pharmaceuticals Filed by: DiFabio Andrea
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/9
Xenon Pharmaceuticals, Inc. (XENE) CEO Simon Pimstone on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha]
6.5%
1/14 Xenon Pharmaceuticals Inc (NASDAQ: XENE) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 6.2%
1/10 Form 8-K Xenon Pharmaceuticals For: Jan 08 5.6%
12/3 Xenon Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference 5.2%
3/2 Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2019 Financial Results and Provide Corporate Update 5.1%
12/11 Form SC 13D Xenon Pharmaceuticals Filed by: NEUROCRINE BIOSCIENCES INC 4.7%
12/2 Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy 4.1%
3/31 Xenon Pharmaceuticals Provides Corporate Update in the Context of COVID-19 3.9%
2/4 Xenon Pharmaceuticals Inc (NASDAQ: XENE) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 3.0%
1/8 Xenon Pharmaceuticals Inc (NASDAQ: XENE) is now covered by analysts at William Blair. They set an "outperform" rating on the stock. 2.6%
1/14 Xenon Pharmaceuticals Inc (NASDAQ: XENE) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 6.2%
1/10 Form 8-K Xenon Pharmaceuticals For: Jan 08 5.6%
12/3 Xenon Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference 5.2%
3/2 Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2019 Financial Results and Provide Corporate Update 5.1%
12/11 Form SC 13D Xenon Pharmaceuticals Filed by: NEUROCRINE BIOSCIENCES INC 4.7%
12/2 Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy 4.1%
3/31 Xenon Pharmaceuticals Provides Corporate Update in the Context of COVID-19 3.9%
2/4 Xenon Pharmaceuticals Inc (NASDAQ: XENE) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 3.0%
1/8 Xenon Pharmaceuticals Inc (NASDAQ: XENE) is now covered by analysts at William Blair. They set an "outperform" rating on the stock. 2.6%
TOP News Decliners
12/2
Form 8-K Xenon Pharmaceuticals For: Dec 02
-12.3%
3/11 Form 8-K Xenon Pharmaceuticals For: Mar 11 -8.9%
1/22 Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares -7.0%
3/13 Form 8-K Xenon Pharmaceuticals For: Mar 12 -6.4%
9/25 Xenon Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference -4.8%
12/5 Xenon Pharmaceuticals Inc (NASDAQ: XENE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -4.3%
12/5 Xenon Pharmaceuticals (XENE) Investor Presentation - Slideshow [Seeking Alpha] -4.3%
2/13 Form SC 13G/A Xenon Pharmaceuticals Filed by: Vivo Opportunity, LLC -4.0%
3/26 Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -3.9%
4/28 Form DEF 14A Xenon Pharmaceuticals For: Jun 01 -2.6%
3/11 Form 8-K Xenon Pharmaceuticals For: Mar 11 -8.9%
1/22 Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares -7.0%
3/13 Form 8-K Xenon Pharmaceuticals For: Mar 12 -6.4%
9/25 Xenon Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference -4.8%
12/5 Xenon Pharmaceuticals Inc (NASDAQ: XENE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -4.3%
12/5 Xenon Pharmaceuticals (XENE) Investor Presentation - Slideshow [Seeking Alpha] -4.3%
2/13 Form SC 13G/A Xenon Pharmaceuticals Filed by: Vivo Opportunity, LLC -4.0%
3/26 Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -3.9%
4/28 Form DEF 14A Xenon Pharmaceuticals For: Jun 01 -2.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: